Amgen Submits Kineret, Enbrel sBLAs; Triangle Files Coviracil NRTI
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amgen’s Kineret Oct. 21 sBLA for a claim to inhibit progression of structural damage in adults with moderately to severely active rheumatoid arthritis is based on a single 12-month, double-blind, placebo-controlled trial.